Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 205 of the 222 references it cites were found in a registry or an index; 39 of the 219 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. PARTICIPANTS: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 μg) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (∼8 mg/m(2)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for diagnosing and treating primary adrenal insufficiency (PAI), emphasizing a low diagnostic threshold, the 250-µg short corticotropin test as the diagnostic gold standard, and glucocorticoid/mineralocorticoid replacement with adrenal crisis prevention. It also highlights major evidence gaps, including sparse randomized trial data for replacement regimens and limited diagnostic accuracy studies specifically in PAI.
Key findings
- For diagnosis, the guideline recommends testing patients with indicative symptoms/signs and using the standard-dose 250-µg corticotropin stimulation test as the “gold standard”; peak cortisol below 500 nmol/L (18 µg/dL) at 30 or 60 minutes indicates adrenal insufficiency. The high-dose ACTH stimulation test had a sensitivity of 92% (95% CI, 81–97%) for PAI based on five studies; no studies were available for the low-dose test in PAI. If corticotropin testing is not feasible, a morning cortisol <140 nmol/L (5 µg/dL) plus ACTH is suggested as a preliminary test.
- Autoimmune adrenalitis is the most common cause of PAI, accounting for up to 90% in Western countries; 21-hydroxylase autoantibodies should be measured, and about 30% of CYP21A2 autoantibody-positive individuals progressed to overt PAI during 5-year follow-up. In autoantibody-negative individuals, other causes should be sought, including adrenoleukodystrophy in males via very-long-chain fatty acids and adrenal CT for infiltrative or malignant disease.
- In adults, recommended replacement is hydrocortisone 15–25 mg/d or cortisone acetate 20–35 mg/d in two or three divided doses, with fludrocortisone starting at 50–100 µg/d (median, 0.1 mg) for confirmed aldosterone deficiency. Prednisolone 3–5 mg/d is an alternative, while dexamethasone is suggested against. DHEA replacement may be tried for 6 months in women with low libido, depressive symptoms, and/or low energy despite optimized replacement.
- For adrenal crisis, immediate parenteral hydrocortisone 100 mg (50 mg/m² for children) is recommended, followed by 200 mg/24 h (50–100 mg/m²/d for children), plus fluid resuscitation. Reported adrenal crisis frequencies were 6.6 crises/100 patient-years in a retrospective analysis of 444 patients and 8.3 crises/100 patient-years in a prospective study of 768 patient-years, with a crisis mortality rate of 0.5/100 patient-years.
Methods
- This is a GRADE-based clinical practice guideline developed by an Endocrine Society Task Force with a methodologist and medical writer; recommendations are graded strong (“we recommend,” 1) or weak (“we suggest,” 2), with evidence quality from QEEE (very low) to QQQQ (high), plus ungraded best practice statements.
- Evidence came from two commissioned systematic reviews and other published systematic reviews/studies. The first review compared high-dose vs low-dose ACTH stimulation for diagnosis and found only five studies for high-dose ACTH in PAI and none for low-dose ACTH in PAI. The second review compared glucocorticoid replacement regimens and identified 15 observational studies; mortality, bone density, and adrenal crisis data were very sparse or unavailable, and there was no statistically significant HRQoL difference between hydrocortisone dosages ≥30 mg/d vs <30 mg/d.
- The guideline was reviewed and approved sequentially by Endocrine Society committees, members responding to a web posting, and the Endocrine Society Council; the Task Force received no corporate funding or remuneration.
Limitations
- The paper states that the evidence base is limited: there are no randomized controlled trials for many treatment questions, diagnostic accuracy data for high-dose ACTH in PAI come from only five studies with none for low-dose ACTH in PAI, and the second systematic review found sparse or unavailable data on mortality, bone density, and adrenal crisis, with very low-quality evidence for extended-release/dual-release glucocorticoids. Many recommendations are weak or ungraded best practice statements.
- The paper states that cortisol cutoff values after corticotropin stimulation vary by assay, ACTH assays have analytical bias, and actual clinical cutpoints should be based on assay-specific normative data.
- Evident from the text: the guideline focuses only on PAI and explicitly excludes secondary adrenal insufficiency and critical illness-related corticosteroid insufficiency; some recommendations rely on clinical experience, unsystematic observations, and values/preferences rather than direct systematic evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]](https://figures.cochat.ai/paper-figures/3d28d00e3ab049b5b513e655fd2f1f7a/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-figure-1.png)
Verification
Claims the paper makes
35 Valid · 2 Not valid · 109 Not checked · 48 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in all these reports, adrenal crisis was a significant cause of death.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Disputedcites [149] 149. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a pop- ulation-based study. J Clin Endocrinol Metab. 2006;91:4849 - 4853. sourceExperimental — accuracy not yet measured
The Mortality section reports 36 deaths attributed to adrenal insufficiency but explicitly says that no patient was reported to have died from adrenal crisis under ICD-10. It also cautions that ICD-9 cannot distinguish adrenal crisis from primary adrenal insufficiency, so the study does not establish crisis as a significant cause of death. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [150] 150. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or com- bined autoimmune primary adrenocortical insufficiency. Clin En- docrinol (Oxf). 2008;69:697-704. source
- Not checked — no full text of the sourcecites [7] 7. Erichsen MM, Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of prema- ture death. Eur J Endocrinol. 2009;160:233-237. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to a paired sample of cortisol and ACTH, the adrenal reserve is appropriately and safely assessed in pregnancy by corticotropin stimulation, if indicated (40,41).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [40] 40. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497-502. source
The Investigations section (p. 3) calls the short Synacthen test a valid measure of adrenal cortisol reserve, including in pregnancy, and says there is no medical reason to avoid a single diagnostic dose in a pregnant woman. The Summary (p. 1) recommends the test when clinically feasible, alongside paired cortisol and ACTH measurements. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [41] 41. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866 -3872. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with diseases such as nephrotic syndrome (43) and liver disease (50) as well as those who are in the immediate postoperative period (51) or who require intensive care (52) may have lower CBG and albumin and hence, lower cortisol measurements.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Not checked — no full text of the sourcecites [43] 43. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocri- nol Metab. 2007;92:1326 -1333. source
- Not checked — no full text of the sourcecites [50] 50. Vincent RP, Etogo-Asse FE, Dew T, Bernal W, Alaghband-Zadeh J, le Roux CW. Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adre- nal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009;46:505-507. source
- Supportedcites [51] 51. le Roux CW, Chapman GA, Kong WM, Dhillo WS, Jones J, Alagh- band-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045- 2048. source
For the part attributed to this source—the immediate postoperative period—the Results report that albumin and CBG fell after surgery, and that seven patients had unexpectedly low postoperative total cortisol. The Discussion attributes those low cortisol values to the fall in CBG. The other conditions in the citing sentence have separate citations. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [52] 52. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350: 1629 -1638. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interpretation of the diagnostic results requires thorough consideration of pregnancy-associated physiological changes of adrenocortical function (42).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [42] 42. Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-1540. source
The Discussion (page not specified in the supplied passage) says that physiological hypercortisolism can be difficult to distinguish from Cushing’s syndrome during pregnancy and emphasizes trimester-specific reference ranges. This supports considering pregnancy-related adrenocortical changes when interpreting diagnostic results. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An elevated ACTH concentration in the presence of a cortisol in the normal range can be the first sign of early-stage PAI (68).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Could not verifycites [68] 68. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discrim- inates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endo- crinol Metab. 2010;95:E263-E270. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that 21-hydroxylase autoantibodies usually precede overt Addison’s disease and proposes subsequent adrenal-function testing. Neither that passage nor the passages retrieved by searching for ACTH, cortisol, and early adrenal insufficiency addresses whether elevated ACTH with normal-range cortisol can be an early sign of PAI. (LLM, conf=0.73)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
118 more claims · 24 with their cited sources checked
Create a free account to see all 194 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 58
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In children, glucocorticoid replacement therapy (GCCrt) should be started with hydrocortisone (HC) at a total daily dose of 10 mg/m2, with dose titration according to individual needs (35).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“no drug suitably mimics the diurnal pattern of cortisol”
From Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells (2018) · cites this paper as Bornstein et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In such cases, a GC dosage increase of 20% to 40% from the 24th week onward is often beneficial (215).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [215]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, no consensus exists regarding the optimal dose and hydrocortisone delivery mode during major stress, and current recommendations are empirical rather than evidence-based (7, 17).”
From Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery (2020) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In primary and secondary adrenal insufficiency, peak cortisol levels < 500 nmol/L (< 18.1 μg/dL), depending on assay, are indicative of adrenal insufficiency (38, 39).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [38]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > 2.2
“We suggest the low-dose (1 g) corticotropin test for diagnosis of PAI only when the substance itself is in short supply.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
“Thus, for practical reasons, the low-dose test may be applicable to situations when corticotropin is in short supply or for other structural or economic reasons.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development of evidence-based guidelines (15).”
MethodSapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541 · cited 1×
“Enhanced glucocorticoid secretion in critical illness is considered necessary to prevent defense mechanisms (eg, cytokine release) from overshooting with concomitant detrimental toxicity (142, 143).”
BackgroundSapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“In newborns and children, mineralocorticoid sensitivity is lower, thereby usually requiring higher fludrocortisone doses compared to adults (106).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 4×
“a 17-OHprogesterone 1000 ng/dL is diagnostic for 21-OH deficiency (14).”
BackgroundMethodInfluentialSelf-citationORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349 · cited 1×
“Serum DHEAS concentrations physiologically peak between ages 20 and 30 years, followed by a gradual decline that is independent of menopause (113).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCorticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033
Marik, P. E., Pastores, S. M., Annane, D., Meduri, G. U., Sprung, C. L., Arlt, W., Keh, D., Briegel, J., Beishuizen, A., Dimopoulou, I., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31817603ba · Cited by 912 · cited 1×
“Although similar arguments for the utility of the low-dose test have been proposed for other special diagnostic challenges such as the detection of adrenal insufficiency in critically ill patients (critical illness-related corticosteroid insufficiency), more evidence is needed to support such a formal recommendation (…”
BackgroundSelf-citationPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
Background
Research works printed but not linked: 3
- [29]29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insuffi- ciency. Ann Intern Med. 2003;139:194 -204.
- [110]110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on miner- alocorticoid replacement with fludrocortisone in adrenal insuffi- ciency. Am J Med Sci. 1986;291:280 -283.
- [177]177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal func- tion in autoimmune Addison's disease: improvement after tetra- cosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.
Cited by
Items 201–300 of 1,752
Irwig, M. S., Fleseriu, M., Jonklaas, J., Tritos, N. A., Yuen, K. C. J., Correa, R. R., Elhomsy, G. C., Garla, V. V., Jasim, S., Soe, K. K., et al. (2020) · Endocrine Practice · doi:10.4158/ps-2019-0540 · Cited by 41
“Clinical practice guidelines are also available for clinicians on the diagnosis and treatment of androgen deficiency, GH deficiency, hypothyroidism, and adrenal insufficiency (10,23,49,50,122).”
BackgroundArioli, F., Gamberini, M. C., Pavlović, R., Cesare, F. D., Draghi, S., Bussei, G., Mungiguerra, F., Casati, A., & Fidani, M. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04249-3 · Cited by 38
“The diagnosis made by biochemical laboratory tests in which blood and/or urine cortisol levels are measured before and after a synthetic form of ACTH is given by injection [44].”
MethodIwasaku, M., Shinzawa, M., Tanaka, S., Kimachi, K., & Kawakami, K. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0208-0 · Cited by 32
“Finally, clinical practice guidelines for AI and AC were just published in 2016 [23, 35], however, our data were from between 2003 and 2014.”
MethodEsposito, S., Marchetti, F., Lanari, M., Caramelli, F., Fanti, A. D., Vergine, G., Iughetti, L., Fornaro, M., Suppiej, A., Zona, S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18083919 · Cited by 37
Hypoglycaemia in adrenal insufficiency
Lee, S. C., Baranowski, E. S., Sakremath, R., Saraff, V., & Mohamed, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1198519 · Cited by 42
A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease
Rahman, A., & Haider, M. F. (2024) · Steroids · doi:10.1016/j.steroids.2024.109440 · Cited by 40
Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
Mongioì, L. M., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2017) · Endocrine Connections · doi:10.1530/ec-17-0368 · Cited by 33
Laugesen, K., Broersen, L. H. A., Hansen, S. B., Dekkers, O. M., Sørensen, H. T., & Jorgensen, J. O. L. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1199 · Cited by 32
Perioperative evaluation and management of patients on glucocorticoids
Chen Cardenas, S. M., Santhanam, P., Morris-Wiseman, L., Salvatori, R., & Hamrahian, A. H. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac185 · Cited by 31
“The dose of GC replacement does not usually need to be increased during the first and second trimesters, but an increase in GC dosage of 20% to 40% from the 24th week forward is generally recommended [166].”
BackgroundImmune checkpoint inhibitor–associated hypercalcaemia
Izzedine, H., Chazal, T., Wanchoo, R., & Jhaveri, K. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa326 · Cited by 35
Bile acids and glucocorticoid metabolism in health and disease
Theiler-Schwetz, V., Zaufel, A., Schlager, H., Obermayer-Pietsch, B., Fickert, P., & Zollner, G. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.001 · Cited by 31
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
Bianchini, M., Puliani, G., Chiefari, A., Mormando, M., Lauretta, R., & Appetecchia, M. (2021) · Cancers · doi:10.3390/cancers13195001 · Cited by 38
“Assessment of adequacy of glucocorticoid replacement therapy should be based on signs and symptoms, a significant change in body weight, postural blood pressure, or electrolyte plasma levels [67].”
BackgroundLabadzhyan, A., Wentzel, K. P., Hamid, O., Chow, K., Kim, S., Piro, L. D., & Melmed, S. K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac161 · Cited by 33
Corticosteroid-binding globulin (CBG): spatiotemporal distribution of cortisol in sepsis
Lee, J. H., Meyer, E. J., Nenke, M., Falhammar, H., & Torpy, D. J. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.002 · Cited by 43
“Survival is threatened in individuals with systemic inflammation if they are deprived of sufficient cortisol [3,4].”
BackgroundSelf-citationAnand, G., & Beuschlein, F. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0975 · Cited by 36
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
Guarnotta, V., Stefano, C. D., Santoro, A., Ciresi, A., Coppola, A., & Giordano, C. S. D. S. (2019) · Endocrine Connections · doi:10.1530/ec-19-0176 · Cited by 35
Wollmer, E., Karkossa, F., Freerks, L., Hetberg, A.-E., Neal, G., Porter, J., Whitaker, M. J., Margetson, D., & Klein, S. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02912-x · Cited by 30
Martella, S., Lucas, M. W., Porcu, M., Perra, L., Denaro, N., Pretta, A., Deias, G., Willard-Gallo, K. E., Parra, H. J. S., Saba, L., et al. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.003 · Cited by 35
Kolli, V., Kim, H., Torky, A., Lao, Q., Tatsi, C., Mallappa, A., & Merke, D. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01661 · Cited by 35
Self-citationMonogenic Forms of Hypertension
Ceccato, F., & Mantero, F. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.009 · Cited by 31
Borresen, S. W., Thorgrimsen, T. B., Jensen, B., Hilsted, L., Bartels, E. M., Feldt‐Rasmussen, U., & Locht, H. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa011 · Cited by 31
Endocrine Dysfunction among Patients with COVID-19
Kumar, B., Gopalakrishnan, M., Garg, M. K., Purohit, P., Banerjee, M., Sharma, P., Khichar, S., Kothari, N., Bhatia, P. K., Nag, V., et al. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_577_20 · Cited by 30
“Adrenal function was assessed by basal cortisol and 1 h post‐intramuscular ACTH (adrenocorticotrophic hormone‐250 μg) cortisol.[20,21] None of the patients had received dexamethasone for respiratory distress as per then existing protocols.”
MethodPediatric Adrenal Insufficiency: Challenges and Solutions
Nisticò, D., Bossini, B., Benvenuto, S., Pellegrin, M. C., & Tornese, G. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s294065 · Cited by 52
“5 to 15 mg/m2/day, divided into two, three, or four doses.(19) The first and largest dose should be taken at awakening, the next in the early afternoon to avoid sleep disturbances.”
BackgroundInfluentialLi, D., Brand, S., Hamidi, O., Westfall, A., Suresh, M., Else, T., Vaidya, A., & Bancos, I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac175 · Cited by 34
Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
Dineen, R., Stewart, P. M., & Sherlock, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13837 · Cited by 30
Kampmeyer, D., Lehnert, H., Moenig, H., Haas, C. S., & Harbeck, B. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.04.006 · Cited by 30
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status
Clarke, S. A., Eng, P. C., Comninos, A. N., Lazarus, K., Choudhury, S., Tsang, C., Meeran, K. M., Tan, T., Dhillo, W. S., & Abbara, A. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae016 · Cited by 38
Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison’s disease
Meyer, G., Koch, M., Herrmann, E., Bojunga, J., & Badenhoop, K. (2018) · Endocrine · doi:10.1007/s12020-017-1513-0 · Cited by 29
Guarnotta, V., Ciresi, A., Pillitteri, G., & Giordano, C. (2018) · Clinical Endocrinology · doi:10.1111/cen.13554 · Cited by 29
Latent Adrenal Insufficiency: Concept, Clues to Detection, and Diagnosis
Yamamoto, T. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0114 · Cited by 36
Katznelson, L. J., & Gadelha, M. R. (2021) · Pituitary · doi:10.1007/s11102-021-01130-x · Cited by 29
Novel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 35
“The recommended substitution dose of HC in patients with adrenal insufficiency is generally 8 – 12 mg/m2/day with increased dosages in case of illness or surgery [2, 25], but for 21OHD patients often higher dosages are necessary to suppress adrenal androgens sufficiently [17].”
BackgroundZha, L., Li, J., Krishnan, S. M., Brennan, M. R., Zhang, Y. V., Povse, P., Kerlin, R., Shively, K., Oleksik, F., Williams, J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.003 · Cited by 34
Tatsi, C., & Stratakis, C. A. (2017) · Clinics in Perinatology · doi:10.1016/j.clp.2017.10.002 · Cited by 36
Self-citationImproved salivary cortisol rhythm with dual-release hydrocortisone
Ceccato, F., Selmin, E., Sabbadin, C., Costa, M. D., Antonelli, G., Plebani, M., Barbot, M., Betterle, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0257 · Cited by 32
Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?
Bornstein, S. R., Steenblock, C., Chrousos, G. P., Schally, A. V., Beuschlein, F., Kline, G. A., Krone, N. P., Licinio, J., Wong, M., Ullmann, E., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0244-9 · Cited by 31
Self-citationSepsis and Adrenal Insufficiency
Fowler, C., Raoof, N. D., & Pastores, S. M. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231183396 · Cited by 34
An integrated single-cell analysis of human adrenal cortex development
del Valle, I., Young, M. D., Kildisiute, G., Ogunbiyi, O. K., Buonocore, F., Simcock, I. C., Khabirova, E., Crespo, B., Moreno, N., Brooks, T., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168177 · Cited by 36
“168177 be fatal if not diagnosed and treated appropriately (9).”
BackgroundInfluentialMondin, A., Ceccato, F., Voltan, G., Mazzeo, P., Manara, R., Denaro, L., Scaroni, C. M., & Barbot, M. (2023) · Pituitary · doi:10.1007/s11102-023-01343-2 · Cited by 31
“The patients received minimal doses of glucocorticoid replacement treatments following BA to avoid both over- and under treatment that might negatively impact survival [43], and this might explain why BA was not associated to increased mortality as observed in other series [44].”
ResultX-linked adrenoleukodystrophy and primary adrenal insufficiency
Cappa, M., Todisco, T., & Bizzarri, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1309053 · Cited by 28
Negri, M., Pivonello, C., Simeoli, C., Gennaro, G. D., Venneri, M. A., Sciarra, F., Ferrigno, R., de Angelis, C., Sbardella, E., Martino, M. C. D., et al. (2020) · Neuroendocrinology · doi:10.1159/000512685 · Cited by 28
Vogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
The adrenal gland microenvironment in health, disease and during regeneration
Kanczkowski, W., Sue, M., & Bornstein, S. R. (2017) · HORMONES · doi:10.14310/horm.2002.1744 · Cited by 41
Self-citationBurgos, N., Ghayee, H. K., & Singh-Ospina, N. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000473 · Cited by 23
Latent Adrenal Insufficiency: From Concept to Diagnosis
Younès, N., Bourdeau, I., & Lacroix, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720769 · Cited by 27
Adrenal Insufficiency in Cirrhosis
Wentworth, B. J., & Siragy, H. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac115 · Cited by 33
“Many authors acknowledge the challenge posed by measuring serum total cortisol (TC) in cirrhosis yet there is insufficient evidence for current guidelines to provide recommendations regarding optimal diagnostic strategies and clinical thresholds [3].”
BackgroundInfluentialA Closer Look at Opioid-Induced Adrenal Insufficiency: A Narrative Review
Coluzzi, F., LeQuang, J. A., Sciacchitano, S., Scerpa, M. S., Rocco, M., & Pergolizzi, J. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054575 · Cited by 36
“9% saline over 1 h followed by infusion as needed), parenteral glucocorticosteroids (100 mg bolus dose of IV hydrocortisone, then 200 to 300 mg of hydrocortisone per day) [10,47].”
BackgroundMushtaq, T., Ali, S., Boulos, N., Boyle, R., Cheetham, T. D., Davies, J. H., Elder, C. J., Gan, H., Hindmarsh, P. C., Katugampola, H., et al. (2023) · Archives of Disease in Childhood · doi:10.1136/archdischild-2022-325156 · Cited by 33
“…or divided doses) 1 month to 11 years: 2–4 mg/kg every 6 hours 12–17 years: 100 mg every 6–8 hours 10 Shulman et al (2006) 24 Nowotny et al (2021) 26 Bornstein et al (2016) 28 Nisticò et al (2021) 27 Woodcock et al (2020) 29 Surgery 50–100 mg/m 2 intravenously or intramuscularly initially…”
BackgroundInfluentialMorelli, V., Minelli, L., Eller-Vainicher, C., Palmieri, S., Cairoli, E., Spada, A., Arosio, M., & Chiodini, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0788-6 · Cited by 30
Specialized Donor Care Facility Model and Advances in Management of Thoracic Organ Donors
Bery, A. I., Marklin, G. F., Itoh, A., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.12.026 · Cited by 26
Cohn, A. Y., Grant, L. K., Nathan, M., Wiley, A., Abramson, M., Harder, J., Crawford, S. L., Klerman, E. B., Scheer, F. A. J. L., Kaiser, U. B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad285 · Cited by 32
Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus
Karaca, Z., Ünlühızarcı, K., & Keleştimur, F. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09847-9 · Cited by 29
Encountering COVID-19 as Endocrinologists
Rhee, E., Kim, J. H., Moon, S. J., & Lee, W. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.197 · Cited by 25
Martino, M., Aboud, N., Cola, M. F., Giancola, G., Ciarloni, A., Salvio, G., & Arnaldi, G. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01422-2 · Cited by 29
A multidisciplinary approach to the management of adrenal incidentaloma
Voltan, G., Boscaro, M., Armanini, D., Scaroni, C. M., & Ceccato, F. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1948327 · Cited by 30
Sharma, H., Sahlot, R., Purwar, N., Garg, U., Saran, S., Sharma, B., & Mathur, S. K. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102405 · Cited by 28
Group 5: Acute adrenal insufficiency in adults and pediatric patients
Cortet, C., Barat, P., Zénaty, D., Guignat, L., & Chanson, P. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.008 · Cited by 37
Therapeutic patient education in adrenal insufficiency
Guignat, L. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.002 · Cited by 28
Shepherd, L. M., Tahrani, A. A., Inman, C., Arlt, W., & Carrick‐Sen, D. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0196-0 · Cited by 34
Self-citationMongioì, L. M., Condorelli, R. A., Barbagallo, F., Cannarella, R., Vignera, S. L., & Calogero, A. E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060806 · Cited by 25
Takayasu, S., Mizushiri, S., Watanuki, Y., Yamagata, S., Usutani, M., Nakada, Y., Asari, Y., Murasawa, S., Kageyama, K., & Daimon, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-05400-x · Cited by 32
Husni, H., Abusamaan, M. S., Dinparastisaleh, R., Sokoll, L., Salvatori, R., & Hamrahian, A. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.978238 · Cited by 26
Pituitary incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.08.006 · Cited by 27
Ramadan fasting in patients with adrenal insufficiency
Chihaoui, M., Chaker, F., Yazidi, M., Grira, W., Amor, Z. B., Rejeb, O., & Slimane, H. (2016) · Endocrine · doi:10.1007/s12020-016-1186-0 · Cited by 27
Glucocorticoid treatment and adrenal suppression in children: current view and open issues
Improda, N., Chioma, L., Capalbo, D., Bizzarri, C., & Salerno, M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02461-9 · Cited by 35
Gleicher, N., Kushnir, V. A., Darmon, S. K., Wang, Q., Zhang, L., Albertini, D. F., & Barad, D. H. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.12.004 · Cited by 24
Metabolic syndrome and endocrine status in HIV-infected transwomen
Pommier, J., Laouenan, C., Michard, F., Papot, E., Urios, P., Boutten, A., Peytavin, G., Ghander, C., Lariven, S., Castanedo, G., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002152 · Cited by 24
Management of Endocrine Emergencies in the ICU
Jacobi, J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019834771 · Cited by 26
Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review
Caetano, C. M., & Malchoff, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.897211 · Cited by 29
Current evidence on the impact of the COVID-19 pandemic on paediatric endocrine conditions
Gnocchi, M., D’Alvano, T., Lattanzi, C., Messina, G., Petraroli, M., Patianna, V. D., Esposito, S., & Street, M. E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.913334 · Cited by 32
Long‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“179,180 However, protocols for the prevention and treatment of adrenal crisis are mainly based on expert opinions and clinical experience, 181 – 184 with differences in the treatment protocols between centres that could potentially impact outcome.”
Adrenal incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.07.017 · Cited by 28
Amrein, K., Martucci, G., & Hahner, S. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4954-2 · Cited by 31
Aguilar-Salinas, C. A., Renner, A., Rojas, C., Samtani, S., & Burotto, M. (2020) · Case Reports in Oncology · doi:10.1159/000507652 · Cited by 25
Nontraumatic adrenal hemorrhage: the adrenal stress
Serafino, M. D., Severino, R., Coppola, V., Gioioso, M., Rocca, R., Lisanti, F., & Scarano, E. (2017) · Radiology Case Reports · doi:10.1016/j.radcr.2017.03.020 · Cited by 24
Kumar, R., Carr, P., & Wassif, W. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138514 · Cited by 23
Ahmet, A. H., Rowan-Legg, A., & Pancer, L. (2021) · Paediatrics & Child Health · doi:10.1093/pch/pxab015 · Cited by 25
An overview of benefits and risks of chronic melanocortin‐1 receptor activation
Böhm, M., Robert, C., Malhotra, S., Clément, K., & Farooqi, I. S. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20269 · Cited by 27
Melvin, A., Chantzichristos, D., Kyle, C. J., Mackenzie, S. D., Walker, B. R., Johannsson, G., Stimson, R. H., & O’Rahilly, S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz277 · Cited by 26
“Although a number of different etiologies are responsible, patients with PAI share common clinical features attributable to deficiency of the respective steroid hormones (25, 29).”
BackgroundGarmes, H. M., Boguszewski, C. L., Miranda, P. A. C., Martins, M. R. A., Correa‐Silva, S. R., Abucham, J., Musolino, N. R. D. C., Vilar, L., Portari, L. H. C., Gadelha, M. R., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000335 · Cited by 31
“2021;65/2 Women with panhypopituitarism and SAI have severe androgen deficiency, although the clinical importance of this finding is still unclear (46,57).”
BackgroundMulatero, P., Groessl, M., Vogt, B., Schumacher, C., Steele, R. E., Brooks, A., Hossack, S., & Brunner, H. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15713 · Cited by 26
“Importantly, none of the plasma cortisol concentrations of the DP13-treated individuals fell within the diagnostic range for adrenal insufficiency (<500 nmol L (1)).(27) Periods of minimal dose exposure should demonstrate consistent target efficacy, that is, aldosterone suppression that not only addresses diurnal aldo…”
BackgroundCongenital Adrenal Hyperplasia
Fraga, N. R., Minaeian, N., & Kim, M. S. (2024) · Pediatrics in Review · doi:10.1542/pir.2022-005617 · Cited by 31
Gleicher, N., Kushnir, V. A., Weghofer, A., & Barad, D. H. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0158-9 · Cited by 25
Health Care Burden in Patients With Adrenal Insufficiency
Gunnarsson, C., Ryan, M. P., Marelli, C., Baker, E. R., Stewart, P. M., Johannsson, G., & Biller, B. M. K. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1064 · Cited by 28
Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?
Graziadio, C., Hasenmajer, V., Venneri, M. A., Gianfrilli, D., Isidori, A. M., & Sbardella, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00434 · Cited by 24
Wollmer, E., Neal, G., Whitaker, M. J., Margetson, D. N., & Klein, S. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.022 · Cited by 23
Pofi, R., Gunatilake, S. S. C., Macgregor, V., Shine, B. S. F., Joseph, R. N., Grossman, A. B., Isidori, A. M., Cudlip, S., Jafar‐Mohammadi, B., Tomlinson, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00406 · Cited by 26
Adrenal Insufficiency in Children With Eosinophilic Esophagitis Treated With Topical Corticosteroids
Bose, P., Kumar, S., Nebesio, T. D., Li, C., Hon, E. C., Atkins, D., Furuta, G. T., & Gupta, S. K. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002537 · Cited by 27
“Patients with a peak cortisol <18 mg/dL by 60 minutes were considered to have an abnormal response to LDST consistent with AI (13) and were referred to pediatric endocrinology for evaluation.”
MethodSignificant barriers to diagnosis and management of adrenal insufficiency in Africa
Mofokeng, T. R. P., Beshyah, S., Mahomed, F. A., Ndlovu, K. C. Z., & Ross, I. L. (2020) · Endocrine Connections · doi:10.1530/ec-20-0129 · Cited by 30
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Kim, Y.-M., Seo, G. H., Kim, G.-H., Ko, J. M., Choi, J., & Yoo, H. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0546-4 · Cited by 22
Evaluation of an individualized education program in pituitary diseases: a pilot study
Albarel, F., Pellegrini, I., Rahabi-Layachi, H., Baccou, C., Gonin, L., Rochette, C., Vermalle, M., Cuny, T., Castinetti, F., & Brue, T. C. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0652 · Cited by 29
Butt, M. I., Alzuhayri, N., Amer, L. G., Riazuddin, M., Aljamei, H. S., Khan, M. S., Abufarhaneh, M., Alrajhi, E., Alnassar, A., AlAhmed, R. S., et al. (2020) · Medicine · doi:10.1097/md.0000000000022621 · Cited by 24
“There is a very subtle risk of diagnosing a patient with hypoadrenalism if 30-minute serum cortisol assessments are avoided (when the result is suboptimal at 60 minutes but normal at 30 minutes); however, in such borderline cases, clinicians often repeat the test([13,15]) although guidelines still recommend it when in…”
ResultNon-PCOS Hyperandrogenic Disorders in Adolescents
Esquivel-Zuniga, M. R., Kirschner, C. K., McCartney, C. R., & Solorzano, C. M. B. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1742259 · Cited by 31
Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies
Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 24
Self-citationWatanabe, T., Ozawa, A., Ishii, S., Tomaru, T., Shibusawa, N., Saito, T., Yamada, E., Horiguchi, K., Nakajima, Y., Matsumoto, S., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej16-0387 · Cited by 22
Use of salivary cortisol and cortisone in the high- and low-dose synacthen test
Elder, C. J., Harrison, R. F., Cross, A. S., Vilela, R., Keevil, B. G., Wright, N. P., & Ross, R. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13509 · Cited by 21
Hypothalamic-Pituitary Axis Function and Adrenal Insufficiency in COVID-19 Patients
Durcan, E., Hacıoğlu, A., Karaca, Z., Ünlühızarcı, K., Gönen, M. S., & Keleştimur, F. (2023) · NeuroImmunoModulation · doi:10.1159/000534025 · Cited by 29
The Chronobiology of Hormone Administration: “Doctor, What Time Should I Take My Medication?”
Colonnello, E., Graziani, A., Rossetti, R., Voltan, G., Masi, D., Lubrano, C., Mariani, S., Watanabe, M., Isidori, A. M., Ferlin, A., et al. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf013 · Cited by 28
Nebenwirkungen der Immun-Checkpoint-Inhibitoren
Foller, S., Oppel-Heuchel, H., Fetter, I., Winkler, Y., & Grimm, M. (2017) · Der Urologe · doi:10.1007/s00120-017-0342-3 · Cited by 22
Metadata
- Authors
- Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J.
- Affiliations
- King's College London (GB)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Royal Adelaide Hospital (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-02
- Volume
- 101
- Issue
- 2
- Pages
- 364-389
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4880116
- OpenAlex
- W2234917292
- Cited by
- 1,769
- References
- 222
- Citations by year
- 2026: 187 · 2025: 198 · 2024: 180 · 2023: 191 · 2022: 180 · 2021: 206 · 2020: 165 · 2019: 149 · 2018: 148 · 2017: 102 · 2016: 54
- FWCI
- 151.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- European Society of Endocrinology
- Novo Nordisk Fonden (NNF14OC0011005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062027)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- Addison's disease, diagnosis, hydrocortisone replacement, fludrocortisone, corticosteroid dose, stress dosing, 21-hydroxylase autoantibodies, autoimmune thyroid disease, pregnancy, glucocorticoid therapy, autoimmune adrenal insufficiency
- MeSH terms
- Adrenal Insufficiency, Female, Humans, Pregnancy, Societies, Medical, Evidence-Based Medicine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.